Pharmaceuticals, Biotechnology & Life Sciences

CEO Ryan Fukushima’s recent 14,286‑share sale at $70 signals liquidity needs or confidence shifts – how will Tempus AI’s AI‑diagnostics growth hold the stock?

Werner Robert F.’s 1,598‑share sell‑to‑cover at $151.42 shows Twist Bioscience’s routine insider tax strategy, not a warning, amid strong growth and investor confidence.

Greenland Mines insider buying: CFO Jeff LeBlanc adds 14,000 shares at $9.72, backing a $2B rare‑earth project and 120% IRR—an undervalued play for long‑term investors.

CEO Troy Edward’s recent Kura Oncology share buy shows strong confidence and aligns management’s interests, hinting at a bullish future.

Insight into Standard BioTools’ insider sales shows liquid‑management, not loss of confidence—watch earnings and contract wins to gauge true upside.

CRINETICS PHARMACEUTICALS insiders buy shares amid bullish run, boosting confidence in its endocrine‑oncology pipeline and upcoming data releases.

CypherPunk’s insider RSU sale shows routine equity liquidity, not a signal of weakness, while the biotech’s oncology pipeline and market‑access strategy remain key to future growth.

CEO Martine Rothblatt’s recent buy of United Therapeutics shares signals confidence at a near‑$513 price—an insider move worth watching for future upside.

EyePoint CFO Elston George trades 5,000 shares in a 2026 insider sale—what his moves reveal about the company’s outlook and governance.

Intercure CFO Cohen Amos exercises 590k options at $1/share, signaling bullish insider confidence amid strong medical‑cannabis growth.